linjc16/ctgov huggingface dataset:
Efficacy of Zingiber Officinalis (Homoeopathic Medicine) in Treatment of Acne Vulgaris

Study Overview
=================
Brief Summary
-----------------
Acne is one of the most common skin problems in teenagers and adolescents. There are many lesser known homoeopathic medicines which have been mentioned in the literature for treatment of acne but their potential has not been properly assessed /documented and therefore these medicines don't form a part of many prescriptions. As a part of this study, efficacy of Zingiber officinalis will be studied in the treatment of Acne vulgaris

Official Title
-----------------
Efficacy of Lesser Known Homoeopathic Medicines in Acne Vulgaris - Zingiber Officinalis

Conditions
-----------------
Acne Vulgaris

Intervention / Treatment
-----------------
* Drug: Zingiber officinalis


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Males and females between 12 to 25 years of age Presence of inflammatory and non-inflammatory lesions Able to follow-up according to protocol Patients not taking any medication for treatment of Acne in preceding one month. Exclusion Criteria: Acne Conglobata Pregnant or Breast feeding females or females having intention of becoming pregnant Significant systemic disease Any drug/ alcohol addiction History of chronic diseases treated with medications in the preceding month which might affect acne condition and treatment outcome

Ages Eligible for Study
-----------------
Minimum Age: 12 Years
Maximum Age: 25 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Zingiber officinalis|To start with subjects will be prescribed Zingiber officinalis in 6 potency to be taken in form of pills 4 times a day for seven days. Dosage and frequency will be changed, if required, based on the condition of subject and their response according to homoeopathic principles.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| percent change in acne lesion counts from the Baseline |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in quality of life of subjects from baseline | Change in Quality of life will be assessed based on Quality of Life Questionnaire to be filled by subjects at the start of Treatment and at the end of time frame. | 6 months | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acne Vulgaris, Homoeopathy, Zingiber officinalis
Quantitative Analysis of Precise Brain Volume in Amyotrophic Lateral Sclerosis

Study Overview
=================
Brief Summary
-----------------
Using the original MRI images of 16 ALS patients and 16 normal controls matched by gender, age and education level in the previous study, the differences of brain volume in different parts of ALS patients and normal controls, and the correlation between brain structure and clinical characteristics were compared by precise brain volume quantitative analysis technology.

Detailed Description
-----------------
This study was a retrospective study. The subjects were 16 ALS patients and 16 normal controls. Previous studies have collected patients' age, gender and education level; The onset site, onset time, bulbar involvement, diagnostic grade, ALSFRS-R score, application of ventilator, application of lirutai, gastrostomy; Age, gender and education level were collected in the control group. Accurate quantitative analysis of brain volume was performed on the original brain MRI images of the two groups.

Official Title
-----------------
Brain Imaging Study of Amyotrophic Lateral Sclerosis Based on Accurate Brain Volume Quantitative Analysis

Conditions
-----------------
Amyotrophic Lateral Sclerosis

Intervention / Treatment
-----------------
* Diagnostic Test: Diagnostic criteria


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Diagnosed ALS patients healthy volunteers Exclusion Criteria: none

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| ALS patients<br> | Diagnostic Test: Diagnostic criteria<br>* Diagnostic criteria of ALS<br>|
| normal controls<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Accurate quantitative analysis of brain volume | Accurate quantitative analysis of brain volume using magnetic resonance brain imaging | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| general situation | Age, gender and education level were collected; Onset site, onset time, involvement of bulbar, diagnostic grade, ALSFRS-R score, application of ventilator, application of lirutai, gastrostomy | 1 day |
An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies

Study Overview
=================
Brief Summary
-----------------
To allow, on a compassionate use basis, zalcitabine (ddC) for pediatric patients with symptomatic HIV disease who have failed treatment or who are intolerant to zidovudine (AZT), or who have completed other ddC protocols, or who are ineligible for ongoing clinical trials.

Detailed Description
-----------------
Patients receive ddC and are evaluated at study entry and every 3 months thereafter, until 3 months after ddC becomes approved for pediatric patients or the sponsor deems it necessary to terminate the protocol.

Official Title
-----------------
An Open-Label Safety Program for the Use of Zalcitabine (Dideoxycytidine; ddC) in Pediatric Patients With Symptomatic HIV Infection Who Have Failed or Are Intolerant to AZT Monotherapy, or Who Have Completed Other ddC Protocols, or Are Ineligible for Other Ongoing Clinical Studies

Conditions
-----------------
HIV Infections

Intervention / Treatment
-----------------
* Drug: Zalcitabine


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria Patients must have: Symptomatic HIV infection. Failure on or intolerance to AZT monotherapy OR completed other ddC protocols OR been ineligible for other ongoing clinical trials. Consent of parent or guardian required. Note: Patients who do not meet the eligibility requirements may discuss their cases with the medical monitor.

Ages Eligible for Study
-----------------
Minimum Age: 3 Months
Maximum Age: 11 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Zalcitabine|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Zalcitabine, Acquired Immunodeficiency Syndrome, AIDS-Related Complex
Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to determine the safety, tolerability, maximum tolerated dose and pharmacokinetics of MLN0128 in patients with Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Official Title
-----------------
A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent MLN0128 in Subjects With Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Conditions
-----------------
Relapsed Multiple Myeloma, Refractory Multiple Myeloma, Waldenstrom Macroglobulinemia

Intervention / Treatment
-----------------
* Drug: MLN0128


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥18 years, including males and females; Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0-2; Life expectancy of ≥3 months; Does not have diabetes and has normal fasting serum glucose and fasting triglycerides ≤ 300 mg/dL For women of child-bearing potential, negative serum pregnancy test within 14 days prior to the first study drug administration and use of physician-approved method of birth control from 30 days prior to the first study drug administration to 30 days following the last study drug administration; Male subjects must be surgically sterile or must agree to use physician-approved contraception during the study and for 30 days following the last study drug administration; Ability to swallow oral medications; Ability to understand and willingness to sign informed consent form prior to initiation of any study procedures; Exclusion Criteria: Have received prior cancer therapy or other investigational therapy within 2 weeks prior to the first administration of study drug. Known impaired cardiac function or clinically significant cardiac disease HIV infection; Failed to recover from the reversible effects of prior anticancer therapies: Pregnancy (positive serum or urine pregnancy test) or breast feeding; Malabsorption due to prior gastrointestinal (GI) surgery, GI disease;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: MLN0128<br> | Drug: MLN0128<br>* MLN0128 administered orally once daily for 28 days<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| determine the dose limiting toxicities |  | 28-days |
Volumetric Study of the Buttocks After Flap Augmentation in Buttocks Lifting

Study Overview
=================
Brief Summary
-----------------
The development of bariatric surgery, its effectiveness and the reduction of complications are at the origin of massive weight loss, the corollary of which has been a clear increase in the demands of treatment of sequelae of weight loss.

Official Title
-----------------
Retrospective Study of Volumetric Gluteal Region by Parasacral Perforator Flaps in Circuferential Body Lift

Conditions
-----------------
Weight Loss

Intervention / Treatment
-----------------
* Procedure: gluteal augmentation with flap in circumferential body lift


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion criteria: 12 months minimum delay with bariatric surgery female, BMI<30kg/m2 Age greater than or equal to 18 years Stable weight for more than 6 months lack of volume in gluetal region agree with clinical trial Exclusion criteria: Patient under tutorship or curatorship Pregnancy or breastfeeding hemoglobinemia< 12g/dL Albuminemia<3,5g/dL active smoking more than 1 month before surgery

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: gluteal augmentation with flap in circumferential body lift|classic circumferential bodylift surgery, using two differents well-known flaps for gluteal augmentation|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| evaluate gluteal volume | evaluate the gluteal volume after augmentation with a parasacral flap using a 3D camera between the preoperative and at 2 months after surgery and 3 months after surgery | 1 day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Surgical complication | Surgical complication during hospitalization, then 15 days after the operation and 1 month after the operation | 1 day | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
plastic and reconstructive surgery, gluteal ptosis, platipygia
Heart Rate Variability Change After Liver Transplantation

Study Overview
=================
Brief Summary
-----------------
Cirrhotic cardiomyopathy describes a hyperdynamic state with the presentation of high cardiac output and low systemic vascular resistance. And the latent heart failure becomes obvious under physiologic and pharmacologic stress. The goal of our study is to assess the effects of liver transplantation on the heart rate variability in patients with end stage liver disease.

Official Title
-----------------
Effects of Liver Transplantation on the Heart Rate Variability in Patients With End-Stage Liver Disease

Conditions
-----------------
Liver Transplantation

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age:18-70y/o receiving liver transplantation Exclusion Criteria: History of cardiovascular disease

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Multiscale entropy | Multiscale entropy was measured at nine time points: 1. preoperative, 2. postoperative day 1, 3. postoperative day 2, 4. postoperative day 3, 5. postoperative day 4, 6. postoperative day 7, 7. postoperative day 14, 8. postoperative 3 months, 9. postoperative 6 months | 6 months |
Impact of Obesity on Postural Control

Study Overview
=================
Brief Summary
-----------------
The goal of the present study was to objectively evaluate the postural behaviour of type II obese patients as compared to adults showing a normal body mass index (BMI) in critical postural tasks.

Conditions
-----------------
Balance, Postural Control, Mechanical Factor

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion: BMI > 35 or BMI < 25 Exclusion: Muscular, neurological or cardiovascular deficits Competitive physical activities

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| control (Body Mass Index < 25)<br> | |
| Obese (Body Mass Index > 35)<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
Serial Measurement of Capillary Blood Lactate in the Management of Sepsis

Study Overview
=================
Brief Summary
-----------------
Determination of capillary lactate by using point-of-care technique is accessible, fast and allows to quantify the circulatory and metabolic dysfunction caused by sepsis. Compared to conventional assay techniques in arterial blood, capillary assay technique may have an increased susceptibility to metabolic alterations induced by sepsis in its initial stages. This increased sensitivity is not necessarily relevant in the management of the most serious patients for whom the diagnosis is obvious, but it could be very useful in patients for whom a diagnosis of severe sepsis or shock have not yet been adopted, particularly to help better identify patients who would require intensive management and avoid the installation of these serious disorders.

Official Title
-----------------
Role of the Serial Measurement of Capillary Blood Lactate in the Management of Sepsis Outside the Intensive Care

Conditions
-----------------
Sepsis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age ≥ 18 years Installation without any plausible explanation of at least one of the following clinical criteria: Chills, fever, mottling, respiratory rate> 20/min; Sat02 < 90% or > 94% with more than 4l O2, heart rate > 90/min,systolic blood pressure < 100 mmHg or 40 mmHg lower compared with normal values, Glasgow coma score < 14. or: .a combination of two (or more) of clinical and laboratory criteria for sepsis. Signed informed consent form Exclusion Criteria: Need in its current treatment of aerosol administration of beta agonists at a frequency greater than one per 8 hours; Targeted therapeutic measures have already stated for more than 60 minutes; Diagnosis other than Sepsis; Malignant neoplasm or other progressive disease and expected survival was less than 3 months.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| measurement of capillary blood lactate |  | 72 hours after inclusion | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Sepsis, Capillary blood lactate, Serial measurement of capillary
Effect of EPBD in ERCP on the Prognosis of Patients With Choledocholithiasis Complicated With Duodenal Papillary Diverticula

Study Overview
=================
Brief Summary
-----------------
The investigators hypothesized that nipple balloon dilatation could make ERCP more successful and reduce postoperative complications and mortality. So the investigators design this experiment on this assumption.

Detailed Description
-----------------
The incidence of periampullary diverticula in patients with choledocholithiasis is very high at 47.1%. A large number of literatures refered that duodenal papillary diverticulum is a high risk factor for postoperative complications and recurrence of choledocholithiasis . Till now, there have been no randomized controlled trials to explore the effect of nipple balloon dilatation (EPLBD) on the treatment and prognosis of patients with choledocholithiasis complicated with periampullary diverticula (found during ERCP).

Official Title
-----------------
EPBD+Small EST VS. Large EST in Patients With Choledocholithiasis Complicated With Duodenal Papillary Diverticula

Conditions
-----------------
Periampullary Diverticula

Intervention / Treatment
-----------------
* Procedure: EPBD
* Procedure: EST


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with choledocholithiasis. 2. During ERCP, the patient was diagnosed as choledocholithiasis combined with duodenal papillary diverticulum. 3. Ages 16 to 75. 4. choledocholithiasis no larger than 1.5 cm Exclusion Criteria: Patients with duodenal papillary tumor. 2. Pregnant. 3. Patients with gastrointestinal duct obstruction endoscopy who cannot be operated and who have endoscopic contraindications. 4. Patients with duodenoscopy contraindications. 5. Patients with severe pancreatitis and other serious diseases.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: EPBD<br>Small incision of the duodenal nipple + EPBD | Procedure: EPBD<br>* Small incision of the duodenal nipple + EPBD<br>|
| Active Comparator: EST<br>Large incision of the duodenal nipple | Procedure: EST<br>* Large incision of the duodenal nipple + EPBD<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of complications | total complications occurded after operation | 1 month | 
| time of operation | duration of the ERCP | 1-4 hours | 
| postoperative recurrent rate | Recurrence rate of choledocholithiasis | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
EPBD